1,720,964 research outputs found
Survival and prognostic factors of early ovarian cancer
No full textSurvival and prognostic factors were analysed in 150 patients with histologically confirmed epithelial ovarian cancer stage IA-IIA. The relapse-free and overall survival rates were, respectively, 81% and 88% after 3 and 74% and 84% after 5 years. The analysis of various prognostic factors indicates as the main factor the grade differentiation of the tumour
Regarding a series of IB bulky cervical cancer treated with neoadjuvant chemotherapy (NACT) and radical hysterectomy and pelvic lymphadenectomy
No full textSurvival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients
No full textRole of secondary surgery in relapsed ovarian cancer
No full textIn recurrent ovarian cancer secondary surgery may be an important opportunity to improve survival and quality of life. In
order to give a general overview of the available evidence, we discuss published data on the role of secondary surgery in relapsing
ovarian cancer. The median survival after secondary surgery has been reported ranging from 16 to 29 months, and seems to be
longer in subjects with optimal debulked disease. However, as with front-line debulking, it is difficult to establish whether the
secondary debulking itself has a therapeutic, or even a lasting palliative effect, or whether the patients in whom the procedure is
successful are those who have more indolent disease. Any benefit of treatment must be compared with potential morbidity.
Post-operative complications are reported in about 25–30% of cases, with a potential impact on hospital stay. During the natural
course of the disease, most patients with ovarian cancer develop intestinal obstruction, without impairment of other vital organs
or pain. Reported series have suggested that palliative surgery for bowel obstruction is generally feasible in most patients. Some
prognostic factors have been suggested to identify patients likely to benefit most from palliative surgery: young age seemed to be
associated with longer survival after successful surgery for bowel obstruction, though this finding was not statistically significant.
The site of obstruction does not seem to be related to survival after surgery
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Pelvic and Paraortic Lymph Nodal Status in Advanced Ovarian Cancer and Survival
No full textBackground. In order to analyze the prognostic role of node
involvement in advanced ovarian cancer, we have analyzed data
from a randomized clinical trial on advanced ovarian cancer.
Methods. Cases were 456 women who entered a randomized
multicentric clinical trial comparing two cisplatin-based schemes
of treatment after cytoreductive surgery for advanced stage III–IV
ovarian cancer. They underwent selective pelvic and/or paraortic
lymphadenectomy.
Results. A total of 161 (35.3%) cases had positive nodes. The
frequency of positive nodes was statistically significantly higher in
FIGO stage IV than in stage III. Also grade 3 tumors were more
likely to have positive nodes than grade 1–2 tumors. No association
was observed between nodal status and response to chemotherapy.
The 3-year survival was 46.2 (standard error (SE) 5 3.4
based on 147 deaths) and 44.6 (SE 5 4.4, based on 84 deaths),
respectively, in negative and positive node groups. The corresponding
values, when the analysis was performed considering
only subjects with residual tumor <1 cm or absent, after first-line
cytoreductive surgery were 66.2 (SE 5 5.7) and 62.4 (SE 5 9.6).
Conclusions. We did not find any association between nodal
status and survival. Particularly, nodal status was not a prognostic
factor for survival in the subgroup of women with residual tumor
<1 cm or absent after cytoreductive surgery
A Phase I/II Study of Topotecan in Combination with Carboplatin in Recurrent Epithelial Ovarian Cancer
No full textObjective. The purpose of this study was to define the maximum
tolerated dose (MTD) of topotecan given as escalating doses combined
to a fixed dosage of carboplatin in late relapsing ovarian
carcinomas.
Methods. Women with relapsing ovarian cancer more than 6
months after first-line treatment were eligible for the study. In the
first phase of the trial, patients were allocated to escalating topotecan
doses with a carboplatin fixed dose (AUC 5, according to
Cockcroft’s formula). If no “severe” adverse event occurred in 1 or
more of the patients, the topotecan dose was increased. The starting
dose of topotecan was 0.50 mg/m2/day, for 3 consecutive days,
and the dose step was of 0.25 mg/m2/day, till 1.5 mg/m2/day. The
study progressed then in a phase II trial.
Results. A total of 39 patients entered the trial. Twenty took
part in the escalating topotecan dose phase (4 per dose level, 0.50,
0.75, 1, 1.25, and 1.50 mg/m2/day) and 19 in the phase II. No
severe adverse event was observed in the phase I of the trial, so the
MTD was not reached. In the phase II trial topotecan was given to
1 mg/m2/day. Overall grade 3–4 neutropenia, lasting 7 days or less,
was observed in 58.9% (23 patients). Thrombocytopenia occurred
in 30.8% (12 patients) and grade 3 anemia in 25.6% (10 patients)
of subjects. No life-threatening event occurred. Platelets or red
blood cell transfusions were given in three cases (7.8%).
Conclusions. This daily-times-3-day schedule of topotecan in
combination with carboplatin is safe
Reproductive factors and risk of uterine fibroids
No full textWe analyzed the relation between reproductive history and risk of uterine fibroids using data from a case-control study. Cases were 621 women with histologically confirmed diagnosis of uterine fibroids. Controls were 1,051 non-hysterectomized patients. Compared with nulliparae, parous women had a relative risk (RR) of fibroids of 0.5 [95% confidence interval (CI) = 0.4-0.6], and the risk declined with number of births. The risk of fibroids also decreased with number of induced abortions (RR = 0.8 and 0.6 for women reporting one or two or more abortions, respectively). A total of 24 cases (3.9%) and 19 controls (1.8%) reported a history of infertility (RR = 2.0; 95% CI = 1.1-3.7)
- …
